Methimazole and risk of acute pancreatitis

Lancet Diabetes Endocrinol. 2020 Mar;8(3):187-189. doi: 10.1016/S2213-8587(20)30025-5. Epub 2020 Feb 5.

Authors

Thomas H Brix¹, Lars C Lund², Daniel P Henriksen³, Lars Folkestad⁴, Steen J Bonnema⁴, Jesper Hallas², Laszlo Hegedüs⁴

Affiliations

¹ Department of Endocrinology, Odense University Hospital, 5000 Odense, Denmark. Electronic address: Thomas.brix@rsyd.dk.
² Clinical Pharmacology and Pharmacy, University of Southern Denmark, Odense, Denmark.
³ Department of Clinical Biochemistry, Odense University Hospital, 5000 Odense, Denmark; Clinical Pharmacology and Pharmacy, University of Southern Denmark, Odense, Denmark.
⁴ Department of Endocrinology, Odense University Hospital, 5000 Odense, Denmark.

PMID: 32035032
DOI: 10.1016/S2213-8587(20)30025-5

No abstract available

Publication types

Letter

MeSH terms

Aged
Aged, 80 and over
Antithyroid Agents / adverse effects*
Cardiovascular Diseases / drug therapy
Cardiovascular Diseases / pathology
Case-Control Studies
Cross-Over Studies
Diabetes Mellitus / drug therapy
Diabetes Mellitus / pathology
Female
Gallstones / drug therapy
Gallstones / pathology
Graves Disease / drug therapy
Graves Disease / pathology
Humans
Liver Diseases, Alcoholic / drug therapy
Liver Diseases, Alcoholic / pathology
Male
Methimazole / adverse effects*
Middle Aged
Pancreatitis / etiology*
Pancreatitis / pathology
Prognosis
Risk Factors

Substances

Antithyroid Agents
Methimazole